An interventional study of Movn Mobile App in Ischemic Heart Disease, Unstable Angina and Systolic Heart Failure, sponsored by University of California, San Francisco. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Supportive care
The purpose of this study is to determine whether using a mobile app increases adherence to a heart healthy prescription after discharge from a cardiac rehab program.
Ongoing maintenance of physical activity after cardiac rehab is an important part of preventing secondary cardiac events in patients with ischemic heart disease. Our central hypothesis is that monitoring and promotion of health-related behaviors by increasing patient-provider communication through a mobile device after discharge from cardiac rehab increased adherence to a heart healthy prescription over time. Participants will be randomly assigned to use a mobile app or serve as the control group. All participants will have an activity tracker to track their activity for two months.
Exclusion Criteria:
Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
Behavioral: Movn Mobile App
Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
Steps Per Day
Physical activity will be measured by steps per day using activity tracker.
Time frame: Two months
6MWT
Physical activity will be measured by a six minute walk test.
Time frame: 2 months
PHQ-9
Depression will be measured by the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 (lowest) to 27 (highest), higher score associated with moderate to severe depression.
Time frame: 2 months
Exercise Self-Efficacy Scale (EXSE)
Self-efficacy will be measured by the Exercise Self-Efficacy Scale (EXSE). Scores can range from 0 (lowest) to 100 (highest) with 0 indicating low self-efficacy and 100 indicating high self-efficacy.
Time frame: 2 months
Acceptability
Satification survey, scored 0 (lowest) to 5 (highest), higher score associated with greater satisfaction
Time frame: 2 months
| Milestone | MVN Group | Usual Care |
|---|---|---|
| Started | 32 | 28 |
| Completed | 26 | 25 |
| Not completed | 6 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Failed primary screening | 3 | 0 |
| Withdrew: Diagnosed with terminal cancer | 1 | 0 |
| Withdrew: Excluded from analysis | 1 | 1 |
Physical activity will be measured by steps per day using activity tracker.
| Steps/day | MVN Group | Usual Care |
|---|---|---|
| Steps Per Day | 8860 ± 5334 | 6633 ± 4684 |
Physical activity will be measured by a six minute walk test.
| meters | MVN Group | Usual Care |
|---|---|---|
| 6MWT | 430 ± 112 | 429 ± 97 |
Depression will be measured by the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 (lowest) to 27 (highest), higher score associated with moderate to severe depression.
| score on a scale | MOVN | Usual Care |
|---|---|---|
| PHQ-9 | 1 (0 to 3) | 2 (0 to 3) |
Self-efficacy will be measured by the Exercise Self-Efficacy Scale (EXSE). Scores can range from 0 (lowest) to 100 (highest) with 0 indicating low self-efficacy and 100 indicating high self-efficacy.
| score on a scale | MVN Group | Usual Care |
|---|---|---|
| Exercise Self-Efficacy Scale (EXSE) | 10 (9.9 to 10) | 9.9 (8.4 to 10) |
Satification survey, scored 0 (lowest) to 5 (highest), higher score associated with greater satisfaction
| Score on a scale | MVN Group | Usual Care |
|---|---|---|
| Fitbit device | 4.83 ± 0.41 | — |
| Movn app | 4.5 ± 0.71 | — |
Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MVN Group | 0/32 (0%) | 1/32 (3.1%) | 0/32 (0%) |
| Usual Care | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Event | MVN Group | Usual Care |
|---|---|---|
| Terminal cancer diagnosis unrelated to studyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/32 | 0/28 |
We enrolled 60 individuals; however, 9 withdrew or were lost to follow-up (6 from the intervention group and 3 from the control group), representing 15% (9/60) attrition.
| Age, Categorical(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 11 | 22 |
| >=65 years | 15 | 14 | 29 |
| Age, Continuous(years) | MVN Group | Usual Care | Total |
|---|---|---|---|
| Mean | 66.7 ± 8.6 | 66.8 ± 8.7 | 66.8 ± 8.7 |
| Sex: Female, Male(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| Female | 6 | 5 | 11 |
| Male | 20 | 20 | 40 |
| Ethnicity (NIH/OMB)(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 25 | 23 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 19 | 22 | 41 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| United States | 26 | 25 | 51 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco